BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 20425776)

  • 1. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 2. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 3. [Epigenetic therapy in myelodysplastic syndromes].
    Maki K; Mitani K
    Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
    Khan H; Vale C; Bhagat T; Verma A
    Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 6. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
    Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ
    J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methyltransferase inhibitors for cancer therapy.
    Brueckner B; Kuck D; Lyko F
    Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
    Tohyama K
    Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
    Steensma DP; Stone RM
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
    Griffiths EA; Gore SD
    Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
    Sekeres MA
    Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract]   [Full Text] [Related]  

  • 15. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
    Cowan LA; Talwar S; Yang AS
    Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
    Lübbert M
    Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
    [No Abstract]   [Full Text] [Related]  

  • 17. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
    Gore SD
    J Natl Compr Canc Netw; 2006 Jan; 4(1):83-90. PubMed ID: 16403407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting DNA methylation.
    Issa JP; Kantarjian HM
    Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
    Ørskov AD; Grønbæk K
    Cancer J; 2017; 23(5):277-285. PubMed ID: 28926428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.